Minocycline treatment for patients with ischemic stroke undergoing thrombectomy
Effects of Minocycline on Patients With Acute Anterior Circulation Ischemic Stroke Undergoing Intravenous Thrombectomy
This study is testing whether the drug minocycline can help protect the brain and improve recovery in people having an ischemic stroke who are getting a thrombectomy.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 180 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Xijing Hospital Academic / other |
| Locations | 1 site (Xi'an) |
| Trial ID | NCT05487417 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of minocycline, a neuroprotective drug, on patients experiencing acute ischemic stroke who are undergoing mechanical thrombectomy. The study aims to determine whether minocycline can reduce cerebral damage and improve patient outcomes by protecting the blood-brain barrier and mitigating ischemia-reperfusion injury. Participants will be monitored for changes in their National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) scores over a three-month period. The trial is designed to explore the potential synergistic effects of minocycline in conjunction with thrombectomy procedures.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-85 with acute anterior circulation ischemic stroke and large vessel occlusion, suitable for mechanical thrombectomy.
Not a fit: Patients with contraindications for mechanical thrombectomy or other major central nervous system diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve recovery outcomes for patients with ischemic stroke.
How similar studies have performed: While minocycline has shown promise in animal models and previous clinical studies, this specific approach in conjunction with mechanical thrombectomy is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with acute cerebral infarction of anterior circulation accompanied by large vessel occlusion; 2. Age 18-85 years old; 3. The time of onset ≤ 6 hours or ≤ 24 hours suitable for mechanical thrombectomy determined by multimodal imaging; 4. The time of onset 6-24 hours, DWI shows an infarct volume less than 1/3 of the MCA blood supply area; the time of onset ≤ 6 hours, the ASPECTS(Alberta Stroke Program Early CT Score) is ≥6; 5. Preoperative NIHSS score ranges from 6 to 30 points; 6. Sign the informed consent form; Exclusion Criteria: 1. There are contraindications for mechanical thrombectomy; 2. No revascularization therapy was performed during the operation or the TICI score after revascularization therapy was less than 2b; 3. There are other major central nervous system diseases, such as brain injury, brain tumor, multiple sclerosis, etc; 4. There is evidence that the patient has bacterial endocarditis, aortic dissection, arteritis or venous cerebral infarction; 5. Renal insufficiency or hepatic insufficiency (serum creatinine \>2.0 mg/dL or 180 µmol/L; liver function greater than 3 times the normal value); 6. Known history of congestive heart failure (requiring dietary or medication changes or hospitalization) within 6 months, or myocardial infarction within 6 months; 7. There is evidence of any other life-threatening or severe diseases that may hinder the completion of the 3-month follow-up and affect the evaluation of the results; 8. Pre-existing neurological deficits or history of dementia; 9. There are infectious diseases that require antibiotic treatment before the disease; 10. Allergic to tetracyclines or unable to take minocycline for other reasons; 11. Minocycline could not be given within 1 hour after recanalization; 12. Pregnant patients; 13. Participated in another clinical trial within 30 days before inclusion in the study. 14. Refuse to sign the informed consent form.
Where this trial is running
Xi'an
- Xijing Hospital — Xi'an, China (Recruiting)
Study contacts
- Study coordinator: Wen Jiang, Ph.D
- Email: jiangwen@fmmu.edu.cn
- Phone: 86-029-84771319
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.